CLOs on the Move

Bostwick Laboratories Inc

www.bostwicklaboratories.com

 
Bostwick Laboratories, Inc. a specialized anatomic pathology laboratory focused on the diagnosis of cancer. The Company delivers diagnostic reports providing physicians with the ability to make treatment decisions with their patients.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Highline Wellness

Were on a mission to make a more pleasant world, one dose at a time. We provide natural, affordable, and effective CBD supplements to give everyone access to a happier, healthier, and more peaceful state of mind and body. Free 2-Day shipping, Lab Test...

Hialeah Technology Center

Hialeah Technology Center is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Southwest General

Southwest General is a 350-bed, non-profit hospital serving southwestern Cuyahoga, northern Medina and eastern Lorain counties. Founded in 1920 by residents of the surrounding communities, Southwest General has a rich history of community partnership and a deep commitment to the health and well-being of the residents it serves. Southwest General is home to nationally recognized physicians, state-of-the-art technology and a full range of medical, surgical and emergency services, including a Level III trauma center. Additionally, patients and families benefit from an extensive program of social services and support groups that provide mental, emotional and spiritual support. All services at Southwest General are provided with an eye toward excellence and individual attention. This is best expressed in Southwest General`s mission statement: Health is our Passion. Quality is our Focus. Compassion is our Way.

McDougall Scientific

McDougall Scientific Ltd is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.